Q4 Announces Strategic Partnership with Rose & Company to Bring New Investor Access Solutions to Listed Companies
16.4.2020 17:30:00 EEST | Business Wire | Press release
Q4 Inc. (Q4), a leading global provider of cloud-based investor relations solutions, and Rose & Company (Rose & Co), the industry’s premier strategic investor relations advisory firm, today announced an exclusive partnership that combines the deep capital markets experience and proven success of Rose & Co’s unique investor access service with Q4’s market-leading IR platform. Together, Q4 and Rose & Co will focus on helping public companies both target and directly engage with institutional investors through an ongoing sales and marketing process.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200416005578/en/
“We are excited to be partnering with Rose & Co, giving our clients the benefit of their extensive capital markets and sell-side experience ” said Darrell Heaps, CEO of Q4. “In a world where IR teams are tasked with doing more with less, this partnership provides significant strategic value and a competitive advantage for our clients through the technology and expertise needed to effectively target and directly engage high quality investors.”
“Q4 offers the best-in-class products and services for investor relations professionals, and we look forward to extending their ability to help listed companies engage with the most appropriate audience of institutional investors,” said Simon Rose, CEO of Rose & Co. “The partnership combines the strengths of two industry leaders to offer the only end-to-end solution for public companies to manage their IR workflow, target desirable shareholders and engage directly with the senior decision makers at institutional money managers around the world.”
The partnership between Q4 and Rose & Co was formed to address the need of public companies, to efficiently and directly engage with the buy-side. By combining thoughtful, proactive investor access with innovative technology, IR teams and executives will be better positioned to access high-quality institutional investors, and to foster productive ongoing relationships with current and prospective shareholders. Further collaboration between the partners will focus on public companies’ investor access needs and the products required to compete in the ever-changing capital markets.
About Q4 Inc.
Q4 is a leading global provider of cloud-based investor relations, with the mission of partnering with customers to achieve their strategic IR objectives. Through best-in-class customer experience and an innovative suite of IR technology, Q4 is a trusted partner to over 2,000 of the world’s largest brands. Q4’s comprehensive portfolio of IR communications and intelligence solutions, supported by an industry-leading customer experience model, empower customers to build impactful and strategic IR programs. Q4 has offices in New York, Toronto, Copenhagen, and London. To learn more, visit: www.q4inc.com.
About Rose & Company
Rose & Company is a strategic advisory firm dedicated to helping clients successfully navigate the global capital markets. We work with our clients to evaluate, define and execute strategies to enhance their presence in increasingly globalized and complex capital markets. For more information, please visit www.roseandco.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200416005578/en/
Contact information
Julia Hanbury | Talk Shop | 604-738-2220 | julia@talkshopmedia.com
Robert Brinberg | Rose & Company | 212-257-5932 | robert@roseandco.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 16:00:00 EEST | Press release
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's core mission has always been to increase access to life-saving treatments. It’s about getting the right information to the right care tea
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 16:00:00 EEST | Press release
Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become operational infrastructure without corresponding security maturity. The report also reveals that AI environments are rapidly becoming more interconnected and business critical. Among organizations adopting AI, 64% now run vector databases, 55
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 16:00:00 EEST | Press release
As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructure to monitor airspace activity. The new 86,350-square-foot facility is a major step in readying supply for multiple, large, global markets. The
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 15:51:00 EEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus ® (ocrelizumab) for Multiple Sclerosis9.7.2026 15:45:00 EEST | Press release
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709701277/en/ “This agreement reflects our focus on pushing high-quality biologics to the finish line efficiently and at scale,” said Anjan Selz, Chief Executive Officer of Polpharma Biologics International AG. “Teva brings reach, discipline and real commercial strength to our strategic collaboration. Combining its global footprint with our technical and develo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom